Profil
David D.
House is Chief Financial Officer at Armata Pharmaceuticals, Inc. starting in 2026.
Former roles include Vice President-Accounting & Controller at ZO Skin Health, Inc. from 2018 to 2024, Controller at Avid Bioservices, Inc., and Senior Auditor at Windes, Inc. Education includes an undergraduate degree from California State University-Fullerton.
Postes actifs de David House
| Sociétés | Poste | Début |
|---|---|---|
| ARMATA PHARMACEUTICALS, INC. | Directeur Financier/CFO | 16/08/2024 |
Anciens postes connus de David House
| Sociétés | Poste | Fin |
|---|---|---|
ZO Skin Health, Inc.
ZO Skin Health, Inc. Household/Personal CareConsumer Non-Durables Manufactures and retails skincare products through online | Comptroller/Controller/Auditor | 01/05/2024 |
| AVID BIOSERVICES, INC. | Comptroller/Controller/Auditor | - |
Windes, Inc.
Windes, Inc. Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Comptroller/Controller/Auditor | - |
Formation de David House
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Avid Bioservices, Inc.
Avid Bioservices, Inc. Pharmaceuticals: MajorHealth Technology Engages in the developing and manufacturing of biologics | Health Technology |
California State University-Fullerton
California State University-Fullerton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Windes, Inc.
Windes, Inc. Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
ZO Skin Health, Inc.
ZO Skin Health, Inc. Household/Personal CareConsumer Non-Durables Manufactures and retails skincare products through online | Consumer Non-Durables |
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on the development and commercialization of novel targeted antimicrobials | Health Technology |
















